LINC02702: A Long Intergenic Non-Protein Coding RNA as a Drug Target and Biomarker

Target Name: LINC02702

NCBI ID: G101929011

LINC02702

Other Name(s): long intergenic non-protein coding RNA 2702 | Long intergenic non-protein coding RNA 2702

LINC02702: A Long Intergenic Non-Protein Coding RNA as a Drug Target and Biomarker

LINC02702 is a long intergenic non-protein coding RNA (lncRNA) that has been identified in various studies as a potential drug target and biomarker. It is a non-coding RNA molecule that is located between the coding regions of two adjacent genes, and it has been shown to play a role in the regulation of various cellular processes. In this article, we will provide an overview of LINC02702, its potential drug target status, and its potential as a biomarker.

Potential Drug Target

LINC02702 has been shown to interact with various protein targets, including the protein known as NF-kappa-B. NF-kappa-B is a transcription factor that plays a role in the regulation of various cellular processes, including inflammation, stress response, and cell survival. LINC02702 has been shown to regulate the activity of NF-kappa-B, which suggests that it may be a potential drug target.

In addition to its potential interaction with NF-kappa-B, LINC02702 has also been shown to interact with other protein targets, including the protein known as PDGF. PDGF is a cytokine that plays a role in the regulation of cell growth, differentiation, and survival. LINC02702 has been shown to regulate the activity of PDGF, which suggests that it may also be a potential drug target.

Potential Biomarker

LINC02702 has also been shown to act as a potential biomarker for various diseases, including cancer. Cancer is a disease that is characterized by the uncontrolled growth and proliferation of cells, and it is a leading cause of death worldwide. LINC02702 has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that it may be a potential biomarker for these diseases.

In addition to its potential as a drug target and biomarker, LINC02702 has also been shown to play a role in the regulation of various cellular processes. It has been shown to regulate the activity of various enzymes, including RNA polymerase II, which is involved in the regulation of gene expression. LINC02702 has also been shown to regulate the activity of various RNA binding proteins, which are involved in the regulation of gene expression.

Conclusion

In conclusion, LINC02702 is a long intergenic non-protein coding RNA that has been shown to interact with various protein targets, including the protein known as NF-kappa-B and PDGF. It has also been shown to act as a potential biomarker for various diseases, including cancer. These findings suggest that LINC02702 may be a valuable drug target and biomarker for the treatment of various diseases. Further research is needed to confirm these findings and to determine the full potential of LINC02702 as a drug.

Protein Name: Long Intergenic Non-protein Coding RNA 2702

The "LINC02702 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02702 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets